# Privia Health Group, Inc.: overview

PRVA · Nasdaq · CIK 1759655 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/prva.md) · [Financials](/companies/prva/financials.md) · [Filings](/companies/prva/filings.md) · [Insiders](/companies/prva/insiders.md)

Latest reported revenue: [$632.6m](/filings/0001759655-26-000064.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, accession 0001759655-26-000064).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [438](/filings/0001759655-25-000110.md) | [461 d](/filings/0001759655-26-000010.md) | [480](/filings/0001759655-26-000029.md) | [521](/filings/0001759655-26-000064.md) | [580](/filings/0001759655-25-000110.md) | [541 d](/filings/0001759655-26-000010.md) | [604](/filings/0001759655-26-000029.md) | [633](/filings/0001759655-26-000064.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [1.3%](/filings/0001759655-25-000110.md) | [1.1% d](/filings/0001759655-26-000010.md) | [1.1%](/filings/0001759655-26-000029.md) | [0.6%](/filings/0001759655-26-000064.md) | [2.5%](/filings/0001759655-25-000110.md) | [2.1% d](/filings/0001759655-26-000010.md) | [1.2%](/filings/0001759655-26-000029.md) | [1.9%](/filings/0001759655-26-000064.md) |
| Net margin | % | [0.8%](/filings/0001759655-25-000110.md) | [1.0% d](/filings/0001759655-26-000010.md) | [0.9%](/filings/0001759655-26-000029.md) | [0.5%](/filings/0001759655-26-000064.md) | [1.2%](/filings/0001759655-25-000110.md) | [1.7% d](/filings/0001759655-26-000010.md) | [0.5%](/filings/0001759655-26-000029.md) | [1.4%](/filings/0001759655-26-000064.md) |
| Diluted EPS | $ per share | [0.03](/filings/0001759655-25-000110.md) | not reported | [0.03](/filings/0001759655-26-000029.md) | [0.02](/filings/0001759655-26-000064.md) | [0.05](/filings/0001759655-25-000110.md) | not reported | [0.02](/filings/0001759655-26-000029.md) | [0.07](/filings/0001759655-26-000064.md) |
| Free cash flow | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [966](/filings/0001759655-24-000022.md) | [1,357](/filings/0001759655-25-000018.md) | [1,658](/filings/0001759655-26-000010.md) | [1,736](/filings/0001759655-26-000010.md) | [2,123](/filings/0001759655-26-000010.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(22.5%)](/filings/0001759655-24-000022.md) | [(1.4%)](/filings/0001759655-25-000018.md) | [1.2%](/filings/0001759655-26-000010.md) | [1.0%](/filings/0001759655-26-000010.md) | [1.6%](/filings/0001759655-26-000010.md) |
| Net margin | % | [(19.5%)](/filings/0001759655-24-000022.md) | [(0.6%)](/filings/0001759655-25-000018.md) | [1.4%](/filings/0001759655-26-000010.md) | [0.8%](/filings/0001759655-26-000010.md) | [1.1%](/filings/0001759655-26-000010.md) |
| Diluted EPS | $ per share | [(1.83)](/filings/0001759655-24-000022.md) | [(0.08)](/filings/0001759655-25-000018.md) | [0.19](/filings/0001759655-26-000010.md) | [0.11](/filings/0001759655-26-000010.md) | [0.18](/filings/0001759655-26-000010.md) |
| Free cash flow | $m | [54.5](/filings/0001759655-24-000022.md) | [47.1](/filings/0001759655-25-000018.md) | [80.7](/filings/0001759655-26-000010.md) | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/prva/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $550.7m | 21,402,417 |  | Added +2,344,507 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $330.6m | 12,848,437 |  | Reduced −197,105 |
| [Durable Capital Partners LP](/funds/1798849.md) | 2026-06-30 | $299.4m | 11,635,948 |  | Reduced −451,895 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $169.1m | 6,572,384 |  | Added +290,842 |
| [Rubicon Founders LLC](/funds/2032489.md) | 2026-06-30 | $153.6m | 5,971,079 |  | Added +22,415 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $132.7m | 5,156,720 |  | Added +147,897 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $126.2m | 4,905,789 |  | Added +415,889 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $80.6m | 3,130,473 |  | Added +234,939 |
| [RIVERBRIDGE PARTNERS LLC](/funds/1112325.md) | 2026-06-30 | $77.2m | 2,998,597 |  | Reduced −919,351 |
| [Bank of New York Mellon Corp](/funds/1390777.md) | 2026-06-30 | $74.4m | 2,892,536 |  | Reduced −50,957 |

## Recent filings

[All 590 filings](/companies/prva/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-08 | 18:48 ET | [SCHEDULE 13D](/filings/0000950103-26-013658.md) | Ownership report, active investor | 0000950103-26-013658 |
| 2026-08-18 | 13:03 ET | [8-K](/filings/0001759655-26-000068.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001759655-26-000068 |
| 2026-08-06 | 12:45 ET | [10-Q](/filings/0001759655-26-000064.md) | Quarterly report, period 2026-06-30 | 0001759655-26-000064 |
| 2026-08-06 | 10:23 ET | [8-K](/filings/0001759655-26-000061.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001759655-26-000061 |
| 2026-07-07 | 20:09 ET | [8-K](/filings/0001759655-26-000056.md) | 5.02 Departure or appointment of officers or directors | 0001759655-26-000056 |
| 2026-05-22 | 12:00 ET | [8-K](/filings/0001759655-26-000034.md) | 5.07 Shareholder vote results | 0001759655-26-000034 |
| 2026-05-07 | 12:58 ET | [10-Q](/filings/0001759655-26-000029.md) | Quarterly report, period 2026-03-31 | 0001759655-26-000029 |
| 2026-05-07 | 10:07 ET | [8-K](/filings/0001759655-26-000027.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001759655-26-000027 |
| 2026-04-02 | 11:55 ET | [DEF 14A](/filings/0001193125-26-138997.md) | Proxy statement, period 2026-05-20 | 0001193125-26-138997 |
| 2026-02-27 | 13:12 ET | [10-K](/filings/0001759655-26-000010.md) | Annual report, period 2025-12-31 | 0001759655-26-000010 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001759655-26-000010.md), filed Feb 27, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/6b32561e-e021-4e07-9f16-a0d4df73824a)

## About the filer

- CIK: 1759655
- Tickers: PRVA
- Exchange: Nasdaq
- SIC code: 8000 Services-Health Services
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.